2011年11月
Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report
ONCOLOGY LETTERS
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 2
- 号
- 6
- 開始ページ
- 1239
- 終了ページ
- 1242
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.3892/ol.2011.369
- 出版者・発行元
- SPANDIDOS PUBL LTD
Polyostotic fibrous dysplasia (PFD) is a high-turnover bone disease that frequently entails chronic bone pain, pathological fractures and severe deformities. Recently, bisphosphonates have shown effective antiresorptive properties in the treatment of children or adults with PFD. We report on a 79-year-old female with PR), who had severe lower limb deformity and chronic bone pain in multiple sites of her extremities for more than 55 years. The patient experienced significant decrease in bone pain and bone turnover markers following long-term (8.5 years) treatment with a low-dose oral alendronate treatment (5 mg/day). To the best of our knowledge, this is the first report of a long-term follow-up of a postmenopausal elderly patient with long-standing symptomatic PFD following continuous low-dose oral alendronate therapy. This case report indicates that long-term daily administration of low-dose alendronate alone is a potential treatment option for elderly patients with PFD, particularly those with long-standing bone pain.
- リンク情報
- ID情報
-
- DOI : 10.3892/ol.2011.369
- ISSN : 1792-1074
- eISSN : 1792-1082
- PubMed ID : 22848294
- Web of Science ID : WOS:000295390800035